Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scient...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	long-acting injectable non-inferiority randomized relapse tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2e783d06a91c488f9fb5a86eeb213adf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e783d06a91c488f9fb5a86eeb213adf
record_format	dspace
spelling	oai:doaj.org-article:2e783d06a91c488f9fb5a86eeb213adf2021-12-02T06:07:15ZEfficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population1178-2021https://doaj.org/article/2e783d06a91c488f9fb5a86eeb213adf2019-02-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-paliperidone-palmitate-3-month-versus-1-month-f-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scientific Affairs, Janssen Cilag EMEA, Neuss, Germany Purpose: This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia. Patients and methods: In this randomized, DB, parallel-group study, adult patients (18–70 years) with schizophrenia (per DSM-IV-TR) having Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120; previously stabilized on PP1M were enrolled. The study had 4 phases: screening (3 weeks), open-label (OL) stabilization (17 weeks), DB (48 weeks) and follow-up (4–12 weeks) phase. Patients were treated with fixed-dose PP3M (175–525 mg eq deltoid/gluteal) or PP1M (50–150 mg eq deltoid/gluteal) for 48 weeks in DB phase. Results: In total, 487 European (PP3M, n=242; PP1M, n=245) and 508 non-European patients (PP3M, n=241; PP1M, n=267) entered DB phase (modified intent-to-treat (mITT) [DB] analysis set). Among the 508 non-European patients in mITT set, 67.7% were from Asia (n=344) and 32.3% were from rest of world (ROW, n=164). During the DB phase, similar percentage of Europeans (PP3M: 7%; PP1M: 8%) and non-Europeans (PP3M: 9%; PP1M: 10%) experienced relapse (Kaplan–Meier estimate PP3M–PP1M [95% CI] of percentage of relapse-free patients at the end of DB phase [primary endpoint]: European: 1.0% [-4.3%; 6.2%]; non-European: 1.4% [-4.4%; 7.1%]; Asian: 1.6% [-5.7%; 9.0%]; and ROW: 1.4% [-7.0%, 9.8%], per-protocol analysis set). Incidence of treatment-emergent adverse events (TEAEs) was lower in Europeans (PP3M: 56%, PP1M: 59%) than non-Europeans (PP3M: 80%, PP1M: 73%). The most commonly reported TEAE was weight gain. Conclusion: PP3M showed similar efficacy to PP1M in Europeans and non-Europeans, consistent with non-inferiority of PP3M to PP1M observed in overall population. Rates of AEs were higher in non-Europeans. However, weight gain was greater in non-Europeans, especially the Asian population. Keywords: long-acting injectable, non-inferiority, randomized, relapse, tolerabilitySavitz AJXu HGopal SNuamah IRavenstijn PHough DHargarter LDove Medical Pressarticlelong-acting injectablenon-inferiorityrandomizedrelapsetolerabilityNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 587-602 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	long-acting injectable non-inferiority randomized relapse tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	long-acting injectable non-inferiority randomized relapse tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Savitz AJ Xu H Gopal S Nuamah I Ravenstijn P Hough D Hargarter L Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
description	Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scientific Affairs, Janssen Cilag EMEA, Neuss, Germany Purpose: This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia. Patients and methods: In this randomized, DB, parallel-group study, adult patients (18–70 years) with schizophrenia (per DSM-IV-TR) having Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120; previously stabilized on PP1M were enrolled. The study had 4 phases: screening (3 weeks), open-label (OL) stabilization (17 weeks), DB (48 weeks) and follow-up (4–12 weeks) phase. Patients were treated with fixed-dose PP3M (175–525 mg eq deltoid/gluteal) or PP1M (50–150 mg eq deltoid/gluteal) for 48 weeks in DB phase. Results: In total, 487 European (PP3M, n=242; PP1M, n=245) and 508 non-European patients (PP3M, n=241; PP1M, n=267) entered DB phase (modified intent-to-treat (mITT) [DB] analysis set). Among the 508 non-European patients in mITT set, 67.7% were from Asia (n=344) and 32.3% were from rest of world (ROW, n=164). During the DB phase, similar percentage of Europeans (PP3M: 7%; PP1M: 8%) and non-Europeans (PP3M: 9%; PP1M: 10%) experienced relapse (Kaplan–Meier estimate PP3M–PP1M [95% CI] of percentage of relapse-free patients at the end of DB phase [primary endpoint]: European: 1.0% [-4.3%; 6.2%]; non-European: 1.4% [-4.4%; 7.1%]; Asian: 1.6% [-5.7%; 9.0%]; and ROW: 1.4% [-7.0%, 9.8%], per-protocol analysis set). Incidence of treatment-emergent adverse events (TEAEs) was lower in Europeans (PP3M: 56%, PP1M: 59%) than non-Europeans (PP3M: 80%, PP1M: 73%). The most commonly reported TEAE was weight gain. Conclusion: PP3M showed similar efficacy to PP1M in Europeans and non-Europeans, consistent with non-inferiority of PP3M to PP1M observed in overall population. Rates of AEs were higher in non-Europeans. However, weight gain was greater in non-Europeans, especially the Asian population. Keywords: long-acting injectable, non-inferiority, randomized, relapse, tolerability
format	article
author	Savitz AJ Xu H Gopal S Nuamah I Ravenstijn P Hough D Hargarter L
author_facet	Savitz AJ Xu H Gopal S Nuamah I Ravenstijn P Hough D Hargarter L
author_sort	Savitz AJ
title	Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
title_short	Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
title_full	Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
title_fullStr	Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
title_full_unstemmed	Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
title_sort	efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between european and non-european population
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/2e783d06a91c488f9fb5a86eeb213adf
work_keys_str_mv	AT savitzaj efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT xuh efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT gopals efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT nuamahi efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT ravenstijnp efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT houghd efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT hargarterl efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation
_version_	1718400042415423488

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Ejemplares similares